Results 131 to 140 of about 16,305 (230)

Correlation between total prostate specific antigen and histological grading of prostate cancer in Kenyan mission hospital: a five-year retrospective review

BMC Urology
Background Prostate cancer (CaP) is the leading non-cutaneous cancer in men of African descent, with the higher mortality rates found in sub-Saharan Africa. Early diagnosis, staging, and management of prostate cancer could help curb its mortality rate in
Chinonso Paul Shu, Marius J. Tchinde, Tsamayem Georter James Sop, Signang Alberic Ndonku, Paul Irungu Juma   +4 more
doaj   +1 more source

The Effect of the Clinical Digital Rectal Exam on the Complexed Prostate-Specific Antigen Versus the Total Prostate-Specific Antigen [PDF]

Background: The total serum prostate-specific antigen has been used as a screening tool to determine prostate health and is routinely done after a clinical exam which may include a digital rectal exam. The complexed prostate-specific antigen is a portion
Brown, Jason Edward
core   +1 more source

Easily Calculate TPSA Descriptors from SMILES Strings Using Ruby CDK

, 2007
A D-F reader wrote in to ask how to calculate Topological Polar Surface Area (TPSA) using Ruby CDK. TPSA is one of the most widely-used descriptors for predicting membrane permeability and from it other important ADME properties. This article shows how to calculate TPSA with Ruby using Ruby CDK.
openaire   +1 more source

494. Evaluation of M3 monoclonal antibody TPSA kit

Japanese Journal of Radiological Technology, 1994
Kachio Kozakai, Hideki Takahashi, Masaaki Takano, Toshio Nakagome, Yoshikazu Miura, Atsushi Senou, Shinji Tanaka   +6 more
openaire   +2 more sources

FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO AS PREDICTOR FOR PROSTATE CARCINOMA

Gomal Journal of Medical Sciences, 2017
Background: Prostate-specific antigen (PSA) is a tumor marker helpful in the diagnosis and follow-up of prostate cancer. Objective of the study was to determine Free/total PSA ratio as a predictor of prostate carcinoma.
Sajjad Ahmad, Abdul Ghafar, Ghazi Khan
doaj  

Primary healthcare-friendly prostate cancer prediction model using routine clinical parameters: a multicenter study. [PDF]

Front Oncol
Chen M, Li T, Yang S, Zhou Y, Lin H, Lan J, Zhang X, Yang X, Zhou J, Lyu G.   +9 more
europepmc   +1 more source

Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules. [PDF]

Biomolecules
Benedetto Tiz D, D'Alì M, Iraci N, Santi C, Sancineto L.   +4 more
europepmc   +1 more source

Diagnostic Efficiency of Age-Adjusted PSAD for Prostate Cancer and Clinically Significant Prostate Cancer: Construction and Nomogram Validation. [PDF]

J Clin Lab Anal
Liu Z, Shan J, Zhang Q, Gao Y, Lv Z, Ma L, Shi H.   +6 more
europepmc   +1 more source

Combination of serum TBL1XR1, MFAP5, and PSA as diagnostic biomarkers for prostate cancer. [PDF]

Clinics (Sao Paulo)
Wu X, Lin X, Lin J.
europepmc   +1 more source

Metabolomics-guided identification of bioactive phytometabolites from South African plants targeting neuroblastoma. [PDF]

Exp Biol Med (Maywood)
Motshudi MC, Naidoo CM, Obi CL, Iweriebor BC, Prinsloo E, Zubair MS, Mkolo NM.   +6 more
europepmc   +1 more source